<DOC>
	<DOCNO>NCT01447628</DOCNO>
	<brief_summary>This study establish whether intravenous iron replacement clinical benefit idiopathic pulmonary arterial hypertension . A 24-week double-blind , randomise , placebo-controlled , crossover study investigate whether single dose 1g Ferinject® CosmoFer improve cardiopulmonary haemodynamics , exercise capacity quality life well-tolerated .</brief_summary>
	<brief_title>IV Iron Replacement Iron Deficiency Idiopathic Pulmonary Arterial Hypertension ( IPAH ) Patients</brief_title>
	<detailed_description>IV iron formulation use Europe - Ferinject IV iron formulation use China - CosmoFer</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>1 . Males female age 1675 year old 2 . PAH idiopathic , heritable associate anorexigens . 3 . Iron deficiency define one follow criterion : sTfR level &gt; 28.1 nmol/l ( sTfR analysis available ) one following : Ferritin &lt; 37 ug/l ; transferrin saturation &lt; 16.4 % ; iron &lt; 10.3 umol/l . 4 . Documented diagnosis PAH right heart catheterisation perform time prior Screening showing : resting mean pulmonary artery pressure &gt; 25mmHg , pulmonary capillary wedge pressure =/ &lt; 15 mm Hg normal reduce cardiac output ; 5 . 6 minute walk distance great 50m entry ; 6 . Stable unchanged PAH therapeutic regime ( combination endothelin receptor antagonist , phosphodiesterase inhibitor prostacyclin analogue ) least 1 month . 7 . Able provide write informed consent prior studymandated procedure 8 . Female subject childbearing potential eligible participate agree use one follow contraception method : Abstinence Contraceptive method failure rate &lt; 1 % : Oral contraceptive , either combined progestogen alone ; Injectable progestogen ; Implants levonorgestrel ; Estrogenic vaginal ring ; Percutaneous contraceptive patch ; Intrauterine device ( IUD ) intrauterine system ( IUS ) meet &lt; 1 % failure rate state product label ; Male partner ( ) sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study ; Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus vaginal spermicidal agent ( foam/gel/film/cream/suppository ) . Exclusion criteria 1 . Unable provide inform consent . 2 . Clinicallysignificant renal disease ( Creatinine clearance &lt; 30 ml/min per 1.73 m2 calculate CKDEpi http : //www.qxmed.com/renal/CalculateCKDEPIGFR.php ) liver disease ( include serum transaminase &gt; 3 time upper limit normal ) . 3 . Haemoglobin concentration &lt; 10 g/dl . 4 . Patients meet follow criterion exclude : Iron &gt; 27 umol/L , Ferritin &gt; 300 ug/L Transferrin saturation &gt; 45 % 5 . Patients moderate severe hypophosphatemia define &lt; 0.65mmol/L 6 . Known haemoglobinopathy e.g . sickle cell disease , thalassaemia . 7 . Admission hospital relate PAH change PAH therapy within 1 month prior Screening . 8 . Evidence leave ventricular disease significant lung disease highresolution CT scan lung function judge investigator 9 . Acute chronic infection inflammation . 10 . Significant uncontrolled asthma judge investigator , eczema atopic allergy . 11 . Females lactate pregnant . 12 . Individuals know HIV , Hepatitis B C CreutzfeldJakob disease . 13 . Known hypersensitivity Ferinject® excipients . 14 . Evidence disturbance utilisation iron . 15 . Significant blood loss ( e.g . GI bleed ) within last 3 month history menorrhagia . 16 . Unable perform Cardiopulmonary Exercise Test i.e . due syncope musculoskeletal factor . 17 . Patients receive investigational medicinal product within 30 day enter baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Idiopathic pulmonary arterial hypertension ( IPAH )</keyword>
	<keyword>Iron deficiency</keyword>
</DOC>